<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152200</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-GO1-005</org_study_id>
    <secondary_id>2019-001346-17</secondary_id>
    <nct_id>NCT04152200</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1</brief_title>
  <acronym>ILLUMINATE-C</acronym>
  <official_title>ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1&#xD;
      (PH1).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Actual">May 18, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Plasma Oxalate from Baseline to Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Pre-dialysis Plasma Oxalate from Baseline to Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Oxalate Area Under the Curve (AUC) Between Dialysis Sessions from Baseline to Month 6 and Month 60</measure>
    <time_frame>Baseline, Month 6; Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Plasma Oxalate from Baseline to Month 6 and Month 60</measure>
    <time_frame>Baseline, Month 6; Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Oxalate from Baseline to Month 6 and Month 60</measure>
    <time_frame>Baseline, Month 6; Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score from Baseline to Month 6 and Month 60</measure>
    <time_frame>Baseline, Month 6; Baseline, Month 60</time_frame>
    <description>Measures core dimensions of health plus role (school) functioning in children. Total score range: 0 - 100; higher scores indicate better health-related quality of life (HRQoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) from Baseline to Month 6 and Month 60</measure>
    <time_frame>Baseline, Month 6; Baseline, Month 60</time_frame>
    <description>KDQOL-36 is a kidney disease-specific measure of HRQoL. Score range (per domain): 0 - 100; higher scores indicate better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (tmax) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (t½β) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (V/F) of Lumasiran</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Oxalate from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nephrocalcinosis from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
    <description>Nephrocalcinosis will be assessed by renal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Dialysis from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mode of Dialysis from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
    <description>Modes of dialysis are defined as hemodialysis and peritoneal dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Renal Stone Events from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function Assessed by Estimated Glomerular Filtration Rate (eGFR) from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Measures of Systemic Oxalosis from Baseline to End of Study</measure>
    <time_frame>Baseline, Month 60</time_frame>
    <description>Systemic oxalosis will be assessed in cardiac, skeletal, ophthalmologic, and dermatologic systems.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Primary Hyperoxaluria Type 1</condition>
  <condition>Primary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Lumasiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive open-label lumasiran.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumasiran</intervention_name>
    <description>Lumasiran will be administered by subcutaneous (SC) injection.</description>
    <arm_group_label>Lumasiran</arm_group_label>
    <other_name>ALN-GO1</other_name>
    <other_name>OXLUMO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has documented diagnosis of primary hyperoxaluria type 1 (PH1)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m^2 for patients ≥12&#xD;
             months of age (&lt;12 months of age, must have serum creatinine considered elevated for&#xD;
             age)&#xD;
&#xD;
          -  Meets plasma oxalate level requirements&#xD;
&#xD;
          -  If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90&#xD;
             days&#xD;
&#xD;
          -  If on dialysis, may be on hemodialysis therapy only and must have been on a stable&#xD;
             regimen for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodialysis/peritoneal dialysis combination therapy or peritoneal dialysis alone&#xD;
&#xD;
          -  Diagnosis of conditions other than PH1 contributing to renal insufficiency&#xD;
&#xD;
          -  History of liver transplant&#xD;
&#xD;
          -  History of kidney transplant and currently receiving immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Irbid</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Yenimahalle</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PH1</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>RNAi Therapeutic</keyword>
  <keyword>siRNA</keyword>
  <keyword>AGT</keyword>
  <keyword>Systemic Oxalosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

